Refine
Is part of the Bibliography
- yes (123) (remove)
Year of publication
- 2014 (123) (remove)
Document Type
- Journal article (75)
- Doctoral Thesis (48)
Keywords
- gene expression (5)
- Epigenetik (4)
- Maus (4)
- Bioinformatik (3)
- Genexpression (3)
- antibodies (3)
- ants (3)
- biodiversity (3)
- cancer (3)
- cytoskeleton (3)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (123) (remove)
Sonstige beteiligte Institutionen
- DNA Analytics Core Facility, Biocenter, University of Würzburg, Würzburg, Germany (1)
- Department of Animal Ecology and Tropical Biology, University of Würzburg, Würzburg, Germany (1)
- Forschungsstation Fabrikschleichach (1)
- Institut für Tierökologie und Tropenbiologie (1)
- Interdisziplinäres Zentrum für Klinische Forschung (ZIKF), Würzburg (1)
- Klinische Mikrobiologie am Universitätsklinikum Erlangen (1)
- Technische Hochschule Wildau (1)
Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis.
In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.